ICER Announces Final Evidence Report for FibroGen’s Roxadustat, Uncertainties Linger
ICER has released a final evidence report for roxadustat, along with policy recommendations. Cardiovascular risks were one of the concerns [...]
Whitepaper on Field Medical Engagement During the COVID-19 Pandemic
Following the annual MAPS (Medical Affairs Professional Society) meeting, select members formed a group to discuss key challenges related to [...]
AMCP Offers Two Virtual Corporate Training Events to Enhance Knowledge of Medicare and PIE Strategies
The AMCP (Academy of Managed Care Pharmacy) will offer two virtual events designed to address knowledge gaps for leaders in [...]
IQVIA Acquires Remaining 40% of Q2 Solutions, $760 Million Deal
IQVIA had previously held 60% of Q2 Solutions and has since acquired the remaining 40% from Quest Diagnostics in a [...]
Whitepaper on Tailoring Your Novel Therapeutic to ICER Standards
ICER (the Institute for Clinical and Economic Review) is an independent nonprofit organization dedicated to the fair evaluation of prescription [...]
ICER Releases Evidence Report on Multiple Myeloma Therapies
ICER has released a new evidence report on CAR T-cell therapies to treat multiple myeloma. All three therapeutics (idecabtagene vicleucel, [...]
Finding Success in the Virtual COVID-19 Meeting Landscape
Dr. Michael Broder, President of HEOR consultancy group PHAR, discusses how the COVID-19 pandemic has altered in-person meetings. While there [...]
NAMCP Short Form on Value Based Care Now Available
The NAMCP Medical Directors Institute recently announced a new Value Based Care Council (VBCC), a subgroup seeking to enhance engagement [...]
Cytel Expands Access to Powerful Computational Solara Software, Will Reduce Clinical Trial Costs
Cytel decision-making software Solara has been opened for general release. It comes in two setups: one for companies with an [...]
Two Online Decision Modelling Courses for Health Economists and Health Professionals
The London School of Hygiene & Tropical Medicine and the University of York have partnered to offer two online courses [...]
Syneos Health and Science 37 Announce Partnership Aimed at RWE Integration Into Clinical Trial Design
In an effort to seamlessly incorporate RWE (real world evidence) into clinical trial design, Syneos Health and Science 37 announced [...]
Pharma Price Negotiations and Reimbursement Hurdles in Germany
Negotiating the prices of Advanced Therapy Medicinal Products (ATMPs) is a challenging and convoluted process in Germany. The majority of [...]
Aurinia Announces ICER’s Favorable Review for Lupus Nephritis Drug
Aurinia Pharmaceuticals announced that ICER (the Institute for Clinical and Economic Review) has released a positive Evidence Report for its [...]
Abbvie HEOR Expert Shares Thoughts on RWE and Improving Health Equity
Christopher Boone, Vice President and global head of HEOR (health economics and research outcomes) at Abbvie, recently gave an informative [...]
Why Does Pharma Make Record Profits From Taxpayer-Funded Research? Does Pricing Regulation Really Impact Innovation?
Vaccines have been developed quickly and efficiently since the start of the COVID-19 pandemic, in part due to taxpayer-supported funding. [...]
FDA Reveals Data Modernization Action Plan Including RWD Details
The FDA released DMAP (a Data Modernization Action Plan) in response to changes and trends in the pharma industry. Some [...]
Can RWE Improve Odds in FDA Applications for Medical Devices?
Christian Howell, Vice President and General Manager of Medical Devices and Diagnostics at Aetion, provides insight into when and how [...]
HealthVerity Conversation Provides Insight Into Pharma, RWE, Payers, and COVID-19
Jared Saul, Global Head of Healthcare and Life Sciences Startups at AWS, discusses the healthcare industry with Andrew Goldberg, Co-founder and COO [...]
Comparing High US Drug Prices to Rest of World is Flawed, Reference Pricing Not a Solution
There are five key points driving high drug prices in the US, including better access in the US and robust [...]
Will States Look to ICER Reports in Legislative Measures to Regulate Drug Prices?
High drug prices are a national crisis. Policymakers in three different states (Washington, Maine, and Hawaii) have introduced price control [...]
How Do Bioisimilars Drive High Drug Prices? Proposed Drug Policy Could Save Americans $360 Billion
One proposed solution for high drug prices in the United States is the use of biosimilars. According to Peter Bach, [...]
The Impact of COVID-19 on Pharma Sales Representatives
As the COVID-19 pandemic continues, the typical day-to-day life of a pharma sales rep has drastically changed. Visiting hospitals to [...]
PRMA Consulting Offers Insight Into US Drug Market and ICER Recommendations
PRMA Consulting has released an eBook detailing the major issues faced by pharmaceutical companies in the United States. Access to [...]
Syneos Health Communications Adds Three Senior Hires to Team
Syneos has added three high-profile hires to their team. Orrin Pollard will take on the role of Director of European [...]
National AHIP Conference Provides Information on Drug Pricing and Health Policy Outlook
The national AHIP (America’s Health Insurance Plans) conference took place earlier this week. It provided important information regarding prescription drug [...]